Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy

Nicola Maurea, Carmela Coppola, Gianluca Ragone, Giuseppe Frasci, Annamaria Bonelli, Carmela Romano, Rosario Vincenzo Iaffaioli

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In many cases, early-stage breast cancer is now curable, and metastatic disease can be chronic consequent to the advent of new therapeutic tools. Unfortunately, some treatments have been associated with adverse cardiovascular effects. Indeed, in many breast cancer survivors, the risk of cardiovascular disease is higher than the risk of cancer recurrence. The clinical challenge of preventing cardiovascular complications in patients undergoing antineoplastic treatment has two aims, more effective life-saving treatment of patients, and prevention of morbidity and cardiovascular mortality in the short term and long term. The aim of the present study is to review the rapidly evolving therapeutic strategies designed to treat early-stage breast cancer. The review highlights the need for more data on the impact of new biological drugs (targeted therapy) on the cardiovascular apparatus. Finally, given the complexity of targeted and other novel treatments, cancer patients are best managed through a multidisciplinary approach.

Original languageEnglish
Pages (from-to)861-868
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Heart Failure
Breast Neoplasms
Light
Therapeutics
Biological Therapy
Antineoplastic Agents
Survivors
Neoplasms
Cardiovascular Diseases
Morbidity
Recurrence
Drug Therapy
Mortality

Keywords

  • breast cancer
  • cardiac insufficiency
  • cardiotoxicity
  • target therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{95c11556f95d4957af7895cfa95372c3,
title = "Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy",
abstract = "In many cases, early-stage breast cancer is now curable, and metastatic disease can be chronic consequent to the advent of new therapeutic tools. Unfortunately, some treatments have been associated with adverse cardiovascular effects. Indeed, in many breast cancer survivors, the risk of cardiovascular disease is higher than the risk of cancer recurrence. The clinical challenge of preventing cardiovascular complications in patients undergoing antineoplastic treatment has two aims, more effective life-saving treatment of patients, and prevention of morbidity and cardiovascular mortality in the short term and long term. The aim of the present study is to review the rapidly evolving therapeutic strategies designed to treat early-stage breast cancer. The review highlights the need for more data on the impact of new biological drugs (targeted therapy) on the cardiovascular apparatus. Finally, given the complexity of targeted and other novel treatments, cancer patients are best managed through a multidisciplinary approach.",
keywords = "breast cancer, cardiac insufficiency, cardiotoxicity, target therapy",
author = "Nicola Maurea and Carmela Coppola and Gianluca Ragone and Giuseppe Frasci and Annamaria Bonelli and Carmela Romano and Iaffaioli, {Rosario Vincenzo}",
year = "2010",
month = "12",
doi = "10.2459/JCM.0b013e328336b4c1",
language = "English",
volume = "11",
pages = "861--868",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Women survive breast cancer but fall victim to heart failure

T2 - The shadows and lights of targeted therapy

AU - Maurea, Nicola

AU - Coppola, Carmela

AU - Ragone, Gianluca

AU - Frasci, Giuseppe

AU - Bonelli, Annamaria

AU - Romano, Carmela

AU - Iaffaioli, Rosario Vincenzo

PY - 2010/12

Y1 - 2010/12

N2 - In many cases, early-stage breast cancer is now curable, and metastatic disease can be chronic consequent to the advent of new therapeutic tools. Unfortunately, some treatments have been associated with adverse cardiovascular effects. Indeed, in many breast cancer survivors, the risk of cardiovascular disease is higher than the risk of cancer recurrence. The clinical challenge of preventing cardiovascular complications in patients undergoing antineoplastic treatment has two aims, more effective life-saving treatment of patients, and prevention of morbidity and cardiovascular mortality in the short term and long term. The aim of the present study is to review the rapidly evolving therapeutic strategies designed to treat early-stage breast cancer. The review highlights the need for more data on the impact of new biological drugs (targeted therapy) on the cardiovascular apparatus. Finally, given the complexity of targeted and other novel treatments, cancer patients are best managed through a multidisciplinary approach.

AB - In many cases, early-stage breast cancer is now curable, and metastatic disease can be chronic consequent to the advent of new therapeutic tools. Unfortunately, some treatments have been associated with adverse cardiovascular effects. Indeed, in many breast cancer survivors, the risk of cardiovascular disease is higher than the risk of cancer recurrence. The clinical challenge of preventing cardiovascular complications in patients undergoing antineoplastic treatment has two aims, more effective life-saving treatment of patients, and prevention of morbidity and cardiovascular mortality in the short term and long term. The aim of the present study is to review the rapidly evolving therapeutic strategies designed to treat early-stage breast cancer. The review highlights the need for more data on the impact of new biological drugs (targeted therapy) on the cardiovascular apparatus. Finally, given the complexity of targeted and other novel treatments, cancer patients are best managed through a multidisciplinary approach.

KW - breast cancer

KW - cardiac insufficiency

KW - cardiotoxicity

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=78649237682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649237682&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e328336b4c1

DO - 10.2459/JCM.0b013e328336b4c1

M3 - Article

C2 - 20072001

AN - SCOPUS:78649237682

VL - 11

SP - 861

EP - 868

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 12

ER -